90 - Interim Assessment of Safety and Immunogenicity From a Proof-of-Concept Phase 2 Trial of an mRNA-Based Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation

Presenting Author(s)

• NI

  Nicolas C. Issa, MD

  M.D
  Brigham & Women's Hospital
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Jessica S. Little, MD (she/her/hers)

  Transplant Infectious Diseases Physician
  Brigham and Women's Hospital
  Boston, MA, United States
• JH

  Jennifer Husson, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• CH

  Chunla He, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• BL

  Benjamin Lorenz, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• 

  Lindsey R. Baden, MD

  Attending Physician
  Brigham and Women's Hospital
  Boston, MA, United States

Presenting Author(s)

• LP

  Lori Panther, MD, MPH

  Senior Director
  Moderna, Inc.
  Cambridge, Massachusetts, United States